Navigation Links
Improving chemotherapy effectiveness by acting on the immune system
Date:12/4/2012

This press release is available in French.

These results reveal how the immune system can then limit the effectiveness of some cancer chemotherapies. The researchers now intend to block the molecules responsible for negative immune system activation to increase the efficiency of chemotherapy. A clinical trial to test this hypothesis should begin very soon.

Chemotherapy is one of the most frequently used treatments to eliminate cancerous cells. These drugs kill all cells that are multiplying, or block their proliferation (for example, cells responsible for hair growth, explaining the hair loss of treated patients). In addition to their direct toxic effects, the chemotherapeutic agents also seem to act on the immune system and could make it possible for the body to trigger a direct antitumor immune response in a second phase. However, this last point is still the subject of hot debate, since some studies suggest, conversely, that chemotherapy eliminates all immune defences.

What now?

The Inserm team directed by Professor Franois Ghiringhelli (Inserm unit 866 "Lipids, nutrition and cancer") from the Georges Franois Leclerc Cancer Research Centre in Dijon observed that two chemotherapeutic agents, 5-fluorouracile and gemcitabine, used to treat colon, breast and pancreas cancers activate a protein complex "inflammasome NLRP3" within some cells in the immune system.

To be more specific, this activation leads to releasing proinflammatory cytokine (interleukin IL-1beta) through these cells. This cytokine "distorts" the immune response related to lymphocytes T and causes the production of another cytokine (cytokine IL-17), which has protumoral properties by encouraging tumour angiogenesis, i.e. vascular irrigation of tumours.

"Our results have made it possible to ascertain that the activation of inflammasome limits the effectiveness of chemotherapy. The challenge was then to see whether we could prevent the activation of inflammasome" explains Franois Ghiringhelli. The researchers then tested two different strategies:

The first was to test the two drugs on inflammasome NLRP3- or cytokine IL-17-deficient mice. In these cases, the researchers showed that antitumor activity was not only present, but it actually increased, demonstrating that these two elements (NLRP3 and IL-17) slow down the chemotherapy action.

The second strategy was to treat the mice using an IL-1beta inhibitor. Here again, the effectiveness of chemotherapy was again increased.

These results suggest that targeting the inflammasome and IL-1beta channels, combined with the use of these two chemotherapy agents, can improve the effectiveness of the latter. These tumour cells are eliminated and, in parallel, the damaging immune responses are deleted.

A therapeutic trial combining 5-fluorouracil and IL-1 beta is currently being prepared and should begin soon at the Georges Franois Leclerc Cancer Research in Dijon.


'/>"/>
Contact: Inserm press office
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related medicine news :

1. Callahan honored for improving older adults health in their doctors offices
2. Air Quality Improving in Many U.S. Cities: Report
3. Cedars-Sinai stroke team earns award for improving regions quality of care
4. Physician-Patient Alliance for Health & Safety: The Path to a Safer PCA Pump - Improving Patient Safety with Integrated Capnography
5. Supporting patient autonomy is critical to improving health
6. Improving the oral health of adults with special needs proves challenging
7. Disability caused by traumatic brain injury in children may persist and stop improving after 2 years
8. Improving quality of life for the bedridden
9. Research from ASCOS Quality Care Symposium shows advances and challenges in improving the quality of cancer care
10. Studies from 2012 Quality Care Symposium highlight findings in improving quality of cancer care
11. U.S. Quit-Smoking Policies Need Improving, Experts Say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... Many individuals looking ... protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved into ... once more, but without the high-carb repercussions. IsoPasta has 30 grams of protein ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in cloud ... Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. ... their small and medium business (SMB) clients. , In recent years, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology: